Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2018 April;59(2) > The Journal of Cardiovascular Surgery 2018 April;59(2):164-71

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  LATEST ADVANCES IN TREATING FEMOROPOPLITEAL DISEASE 

The Journal of Cardiovascular Surgery 2018 April;59(2):164-71

DOI: 10.23736/S0021-9509.17.10210-7

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Anticoagulation and antiplatelet therapy in patients with peripheral arterial disease of the femoropopliteal arteries

Cornelis G. VOS , Anco C. VAHL

Department of Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands


PDF


Peripheral arterial disease (PAD) is associated with a substantial cardiovascular risk and secondary prevention is recommended for all patients. In this report, the literature on anticoagulant and antiplatelet drugs for patients with PAD in the femoro-popliteal segment is reviewed. PubMed/MEDLINE and Cochrane Database was searched for studies published between January 1966 and August 2017. Meta-analyses and randomized controlled trials describing outcome of anticoagulants or antiplatelet drugs for secondary prevention or following vascular interventions in patients with PAD were included. All patients with PAD should receive antiplatelet therapy to reduce cardiovascular risk with a slight preference for clopidogrel monotherapy. Following intervention, most patients will continue to benefit from this treatment. Patients receiving a venous bypass graft will benefit from VKA treatment and those with a below-knee prosthetic bypass graft should receive dual antiplatelet therapy (acetylsalicylic acid combined with clopidogrel). Further sufficiently powered studies are needed to further explore the optimal medical treatment for patients that undergo vascular interventions.


KEY WORDS: Peripheral arterial disease - Anticoagulants - Secondary prevention - Risk management - Vascular patency

top of page